Spero Therapeutics, Inc. (SPRO) stock
Close on Nov 11, 2026Market cap $59.40MP/E 25.5Yield –
Spero Therapeutics, Inc. saw revenue fall 3.3% to $47.00M over the twelve months to Jun 30, 2026. At the latest close the market valued the company at $59.40M, 25.5 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $59.40M
- P/E ratio
- 25.5
- Price to sales
- 1.26
- Price to book
- 1.34
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $47.00M
- Net income
- $7.38M
- EPS, diluted
- $0.04
- Book value per share
- $0.76
- Diluted shares
- 58M
Trading
- Next earnings
- Nov 12, 2026 (estimated, during market hours)
- Previous close
- $1.01
- Open
- $1.03
- Day's range
- $1.01 – $1.05
- Volume
- 158,509
- Average volume (20 days)
- 331,374
- Beta (5 years)
- 1.13
- 52-week range
- $0.96 – $3.08
- RSI (14 days)
- 41.2
- Volatility (1 year)
- 64.2%
- Relative volume
- 0.16×
- WACC
- 10.5%
Market cap history
Month-end market cap since 2017, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | SPRO | S&P 500 | Difference | SPRO per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -15.0% | -2.4% | −12.6 pts | ||
| 3 months | -17.1% | -1.2% | −15.9 pts | ||
| Year to date | -56.2% | +12.3% | −68.5 pts | ||
| 1 year | -61.1% | +12.4% | −73.5 pts | ||
| 3 years | -8.1% | +78.8% | −86.9 pts | -2.8% | +21.4% |
| 5 years | -94.0% | +75.2% | −169.1 pts | -43.0% | +11.9% |
Twelve years at a glance
Fiscal years 2014 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Spero Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Update
- Update
- Results
About Spero Therapeutics
Pharmaceutical Preparations
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on identifying and developing treatments for rare diseases and conditions with high unmet medical need. The company's lead clinical-stage product candidate is tebipenem HBr, an oral carbapenem intended for the treatment of complicated urinary tract infections, including pyelonephritis, caused by certain microorganisms in adult patients with limited oral treatment options. Spero previously developed SPR206 for bacterial pneumonia and SPR720 for nontuberculous mycobacterial pulmonary disease, but ceased development of both programs to concentrate resources on advancing tebipenem HBr in collaboration with partner GlaxoSmithKline.
Company profile, executives and historySpero Therapeutics stock: common questions
What is Spero Therapeutics's stock price?
SPRO closed at $1.02 on Nov 11, 2026, up 0.99% on the day. Over the past 52 weeks it traded between $0.96 and $3.08.
What is Spero Therapeutics's market cap?
Spero Therapeutics was worth $59.40M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is SPRO's P/E ratio?
SPRO trades at 25.5 times earnings, based on diluted earnings per share of $0.04 over the twelve months to Jun 30, 2026.
How much revenue does Spero Therapeutics make?
Spero Therapeutics reported revenue of $47.00M for the twelve months to Jun 30, 2026, down 3.3% from a year earlier.
Does Spero Therapeutics pay a dividend?
No. Spero Therapeutics has not paid a cash dividend over the last twelve months.
When does Spero Therapeutics report earnings next?
Spero Therapeutics is expected to report Q3 FY2026 results on Nov 12, 2026, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has SPRO stock performed over the past year?
Including dividends, SPRO returned -61.1% over the past year, against +12.4% for the S&P 500.
How many SPRO shares are sold short?
1M shares were sold short at the latest FINRA report, 1.79% of the float, or 2.2 days of average trading volume.
Who are Spero Therapeutics's competitors?
Companies most similar to Spero Therapeutics by business, industry and size include GOSS, FULC, OCUL, TNGX, NKTR.
See a number that looks wrong?